Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Common Equity of $28.4 million for Q1 2026, up 631.03% year-over-year from $3.9 million in Q1 2025, and down 13.95% quarter-over-quarter from $33.0 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Common Equity history runs 7 years deep, the most recent figure standing at $28.4 million for Q1 2026.
- In Q1 2026, Common Equity rose 631.03% year-over-year to $28.4 million; the TTM figure through Mar 2026 stood at $28.4 million (up 631.03% YoY), while the FY2025 annual figure was $33.0 million, up 845.03% from the prior year.
- Common Equity for Q1 2026 stood at $28.4 million, down from $33.0 million in the prior quarter.
- The five-year high for Common Equity was $110.6 million in Q1 2022, with the low at -$12.0 million in Q3 2025.
- The 5-year median for Common Equity is $28.4 million (2026), against an average of $35.5 million.
- Peak annual rise in Common Equity reached 845.03% in 2025, while the deepest fall reached 307.32% in 2025.
- Rani Therapeutics Holdings' Common Equity stood at $74.0 million in 2022, then plunged by 65.62% to $25.4 million in 2023, then sank by 86.27% to $3.5 million in 2024, then surged by 845.03% to $33.0 million in 2025, then dropped by 13.95% to $28.4 million in 2026.
- Business Quant data shows RANI's Common Equity at $28.4 million in Q1 2026, $33.0 million in Q4 2025, and -$12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | Rani Therapeutics Holdings | 160.98 Mn | 160.98 Mn | - | 47.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.99 Mn |
| Mar 31, 2026 | 28.41 Mn |
| Dec 31, 2025 | 33.01 Mn |
| Sep 30, 2025 | -11.97 Mn |
| Jun 30, 2025 | -9.15 Mn |
| Mar 31, 2025 | -5.35 Mn |
| Dec 31, 2024 | 3.49 Mn |
| Sep 30, 2024 | 5.78 Mn |
| Jun 30, 2024 | 5.55 Mn |
| Mar 31, 2024 | 14.54 Mn |
| Dec 31, 2023 | 25.44 Mn |
| Sep 30, 2023 | 34.82 Mn |
| Jun 30, 2023 | 48.17 Mn |
| Mar 31, 2023 | 61.59 Mn |
| Dec 31, 2022 | 74.00 Mn |
| Sep 30, 2022 | 86.61 Mn |
| Jun 30, 2022 | 98.65 Mn |
| Mar 31, 2022 | 110.64 Mn |
| Dec 31, 2021 | 121.57 Mn |
| Sep 30, 2021 | 131.71 Mn |